Previous 10 | Next 10 |
SAN DIEGO, May 13, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that three abstracts highlighting its drug candidate tipifarnib h...
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...
SAN DIEGO, May 07, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its participation at the BofA Securities Virtual Healthcare Confe...
Kura Oncology ( KURA -4.5% ) has priced its underwritten public offering of 9.1M common shares at $13.75/share. More news on: Kura Oncology, Inc., Healthcare stocks news, , Stocks on the move Read more ...
SAExploration Holdings (NASDAQ: SAEX ) -25% . More news on: SAExploration Holdings, Inc., My Size, Inc., Pinterest, Inc., Stocks on the move, , Read more ...
SAN DIEGO, May 06, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced the pricing of an underwritten public offering of 9,100,000 share...
Kura Oncology (NASDAQ: KURA ) has commenced a public offering to issue and sell shares of its common stock. More news on: Kura Oncology, Inc., Healthcare stocks news, , Read more ...
Image source: The Motley Fool. Kura Oncology, Inc. (NASDAQ: KURA) Q1 2020 Earnings Call May 4, 2020 , 4:30 p.m. ET Operator Continue reading
Aurinia Pharmaceuticals (AUP CN) initiated with Outperform rating and C$30 (29% upside) price target at Cowen and Company. No premarket activity yet (NASDAQ: AUPH ) in U.S. More news on: Aurinia Pharmaceuticals Inc., Blueprint Medicines Corporation, Cytokinetics, Incorporated, Healthcare s...
Kura Oncology, Inc. (KURA) Q1 2020 Earnings Conference Call May 04, 2020 4:30 PM ET Company Participants Pete De Spain - Vice President of Investor Relations Troy Wilson - President & Chief Executive Officer Marc Grasso - Chief Financial Officer & Chief Business Officer ...
News, Short Squeeze, Breakout and More Instantly...
2024-06-25 22:48:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-25 08:15:04 ET H.C. Wainwright analyst issues BUY recommendation for KURA on June 25, 2024 06:44AM ET. The previous analyst recommendation was Buy. KURA was trading at $21.08 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current...
– Ziftomenib induces insulin production, improves insulin sensitivity and reduces insulin resistance in preclinical model of type 2 diabetes – – Kura advancing multiple, next-generation menin inhibitor drug candidates targeting diabetes and other metabolic diseases ...